Phase I Study of MOv18 IgE

Summary

This first in human study of the new therapeutic antibody MOv18 immunoglobulin (Ig) E, which targets a protein called folate receptor alpha (FRa), in patients with advanced cancer seeks to demonstrate the potential for the use of this IgE antibody as an example of the use of the IgE class of antibodies for the treatment of cancer.

Timeline

Start

2016-02-16

Primary completion

2021-06-22

Completion

2021-07-30

Publications

• Stavraka C, Chauhan J, Crescioli S, McSweeney SM, Pope A, Gillett C, Di Meo A, Prassas I, Laddach R, Stoker K, McCraw AJ, Adams R, Tull TJ, Naban N, Willsmore Z, Semkova KV, Grattan CEH, McGrath J, Till SJ, Corrigan CJ, Kristeleit R, Tsoka S, Diamandis EP, Lacy KE, Pinder S, Josephs DH, Spicer J, Bax HJ, Karagiannis SN. Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha. Allergy. 2025 Aug;80(8):2225-2239. doi: 10.1111/all.16514. Epub 2025 Mar 6.
• Bax HJ, Chauhan J, McCraw AJ, Grandits M, Stavraka C, Lentfer H, Hillyer T, Carroll S, Vigor K, Selkirk C, Figini M, Cheeseman J, Urbanowicz PA, Gardner RA, Spencer DIR, Westwood N, Mellor S, Spicer J, Josephs DH, Karagiannis SN. Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production. MAbs. 2025 Dec;17(1):2451295. doi: 10.1080/19420862.2025.2451295. Epub 2025 Jan 20.
• Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, Veal GJ, Corrigan CJ, Till SJ, Figini M, Canevari S, Barton C, Jones P, Mellor S, Carroll S, Selkirk C, Nintos G, Kwatra V, Funingana IG, Doherty G, Gould HJ, Pellizzari G, Nakamura M, Ilieva KM, Khiabany A, Stavraka C, Chauhan J, Gillett C, Pinder S, Bax HJ, Josephs DH, Karagiannis SN. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial. Nat Commun. 2023 Jul 25;14(1):4180. doi: 10.1038/s41467-023-39679-9.

Drugs

Indications

No indication recorded.